Entrada Therapeutics Analyst Ratings
Entrada Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/27/2023 | 72.56% | HC Wainwright & Co. | $25 → $20 | Maintains | Buy |
| 09/22/2023 | 115.7% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 08/09/2023 | 115.7% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 08/02/2023 | 115.7% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 05/24/2023 | 115.7% | HC Wainwright & Co. | → $25 | Reiterates | Buy → Buy |
| 04/03/2023 | 115.7% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 11/08/2022 | 55.31% | Goldman Sachs | $13 → $18 | Maintains | Neutral |
| 08/16/2022 | 12.17% | Goldman Sachs | $10 → $13 | Maintains | Neutral |
| 05/24/2022 | -13.72% | Goldman Sachs | $22 → $10 | Maintains | Neutral |
| 11/24/2021 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/23/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/23/2021 | 150.22% | Goldman Sachs | → $29 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/27/2023 | 72.56% | HC Wainwright & Co. | 25 美元 → 20 美元 | 維護 | 買 |
| 09/22/2023 | 115.7% | HC Wainwright & Co. | → 25 美元 | 重申 | 購買 → 購買 |
| 08/09/2023 | 115.7% | HC Wainwright & Co. | → 25 美元 | 重申 | 購買 → 購買 |
| 08/02/2023 | 115.7% | HC Wainwright & Co. | → 25 美元 | 重申 | 購買 → 購買 |
| 05/24/2023 | 115.7% | HC Wainwright & Co. | → 25 美元 | 重申 | 購買 → 購買 |
| 04/03/2023 | 115.7% | HC Wainwright & Co. | → 25 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 8 月 11 日 | 55.31% | 高盛 | 13 美元 → 18 美元 | 維護 | 中立 |
| 08/16/2022 | 12.17% | 高盛 | 10 美元 → 13 美元 | 維護 | 中立 |
| 2022 年 5 月 24 日 | -13.72% | 高盛 | 22 美元 → 10 美元 | 維護 | 中立 |
| 11/24/2021 | — | Evercore ISI 集團 | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 11/23/2021 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 11/23/2021 | 150.22% | 高盛 | → 29 美元 | 啓動覆蓋範圍開啓 | → 中立 |
What is the target price for Entrada Therapeutics (TRDA)?
Entrada Therapeutics（TRDA）的目標價格是多少？
The latest price target for Entrada Therapeutics (NASDAQ: TRDA) was reported by HC Wainwright & Co. on November 27, 2023. The analyst firm set a price target for $20.00 expecting TRDA to rise to within 12 months (a possible 72.56% upside). 6 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月27日公佈了Entrada Therapeutics（納斯達克股票代碼：TRDA）的最新目標股價。該分析公司將目標股價定爲20.00美元，預計TRDA將在12個月內升至12個月內（可能上漲72.56％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Entrada Therapeutics (TRDA)?
分析師對Entrada Therapeutics（TRDA）的最新評級是多少？
The latest analyst rating for Entrada Therapeutics (NASDAQ: TRDA) was provided by HC Wainwright & Co., and Entrada Therapeutics maintained their buy rating.
HC Wainwright & Co. 提供了Entrada Therapeutics（納斯達克股票代碼：TRDA）的最新分析師評級，Entrada Therapeutics維持買入評級。
When is the next analyst rating going to be posted or updated for Entrada Therapeutics (TRDA)?
Entrada Therapeutics（TRDA）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entrada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entrada Therapeutics was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Entrada Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Entrada Therapeutics的最新評級是在2023年11月27日公佈的，因此您應該預計下一個評級將在2024年11月27日左右公佈。
Is the Analyst Rating Entrada Therapeutics (TRDA) correct?
分析師對Entrada Therapeutics（TRDA）的評級是否正確？
While ratings are subjective and will change, the latest Entrada Therapeutics (TRDA) rating was a maintained with a price target of $25.00 to $20.00. The current price Entrada Therapeutics (TRDA) is trading at is $11.59, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Entrada Therapeutics（TRDA）評級維持不變，目標股價爲25美元至20.00美元。Entrada Therapeutics（TRDA）目前的交易價格爲11.59美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。